Cargando…

Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study

The aim of this study was to investigate the effects of 24-week synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes. We randomized 88 obese patients with type 2 diabetes to one of two groups for 24 weeks: control or synbiotic (Lacticaseibac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanazawa, Akio, Aida, Masanori, Yoshida, Yasuto, Kaga, Hideyoshi, Katahira, Takehiro, Suzuki, Luka, Tamaki, Shoko, Sato, Junko, Goto, Hiromasa, Azuma, Kosuke, Shimizu, Tomoaki, Takahashi, Takuya, Yamashiro, Yuichiro, Watada, Hirotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914668/
https://www.ncbi.nlm.nih.gov/pubmed/33567701
http://dx.doi.org/10.3390/nu13020558
_version_ 1783657057253064704
author Kanazawa, Akio
Aida, Masanori
Yoshida, Yasuto
Kaga, Hideyoshi
Katahira, Takehiro
Suzuki, Luka
Tamaki, Shoko
Sato, Junko
Goto, Hiromasa
Azuma, Kosuke
Shimizu, Tomoaki
Takahashi, Takuya
Yamashiro, Yuichiro
Watada, Hirotaka
author_facet Kanazawa, Akio
Aida, Masanori
Yoshida, Yasuto
Kaga, Hideyoshi
Katahira, Takehiro
Suzuki, Luka
Tamaki, Shoko
Sato, Junko
Goto, Hiromasa
Azuma, Kosuke
Shimizu, Tomoaki
Takahashi, Takuya
Yamashiro, Yuichiro
Watada, Hirotaka
author_sort Kanazawa, Akio
collection PubMed
description The aim of this study was to investigate the effects of 24-week synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes. We randomized 88 obese patients with type 2 diabetes to one of two groups for 24 weeks: control or synbiotic (Lacticaseibacillus paracasei strain Shirota (previously Lactobacillus casei strain Shirota) and Bifidobacterium breve strain Yakult, and galactooligosaccharides). The primary endpoint was the change in interleukin-6 from baseline to 24 weeks. Secondary endpoints were evaluation of the gut microbiota in feces and blood, fecal organic acids, high-sensitivity C-reactive protein, lipopolysaccharide-binding protein, and glycemic control. Synbiotic administration for 24 weeks did not significantly affect changes in interleukin-6 from baseline to 24 weeks (0.35 ± 1.99 vs. −0.24 ± 1.75 pg/mL, respectively). Relative to baseline, however, at 24 weeks after synbiotic administration there were positive changes in the counts of Bifidobacterium and total lactobacilli, the relative abundances of Bifidobacterium species such as Bifidobacterium adolescentis and Bifidobacterium pseudocatenulatum, and the concentrations of acetic and butyric acids in feces. No significant changes in inflammatory markers were found in the synbiotic group compared to the control group. However, synbiotic administration at least partially improved the gut environment in obese patients with type 2 diabetes.
format Online
Article
Text
id pubmed-7914668
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79146682021-03-01 Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study Kanazawa, Akio Aida, Masanori Yoshida, Yasuto Kaga, Hideyoshi Katahira, Takehiro Suzuki, Luka Tamaki, Shoko Sato, Junko Goto, Hiromasa Azuma, Kosuke Shimizu, Tomoaki Takahashi, Takuya Yamashiro, Yuichiro Watada, Hirotaka Nutrients Article The aim of this study was to investigate the effects of 24-week synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes. We randomized 88 obese patients with type 2 diabetes to one of two groups for 24 weeks: control or synbiotic (Lacticaseibacillus paracasei strain Shirota (previously Lactobacillus casei strain Shirota) and Bifidobacterium breve strain Yakult, and galactooligosaccharides). The primary endpoint was the change in interleukin-6 from baseline to 24 weeks. Secondary endpoints were evaluation of the gut microbiota in feces and blood, fecal organic acids, high-sensitivity C-reactive protein, lipopolysaccharide-binding protein, and glycemic control. Synbiotic administration for 24 weeks did not significantly affect changes in interleukin-6 from baseline to 24 weeks (0.35 ± 1.99 vs. −0.24 ± 1.75 pg/mL, respectively). Relative to baseline, however, at 24 weeks after synbiotic administration there were positive changes in the counts of Bifidobacterium and total lactobacilli, the relative abundances of Bifidobacterium species such as Bifidobacterium adolescentis and Bifidobacterium pseudocatenulatum, and the concentrations of acetic and butyric acids in feces. No significant changes in inflammatory markers were found in the synbiotic group compared to the control group. However, synbiotic administration at least partially improved the gut environment in obese patients with type 2 diabetes. MDPI 2021-02-08 /pmc/articles/PMC7914668/ /pubmed/33567701 http://dx.doi.org/10.3390/nu13020558 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kanazawa, Akio
Aida, Masanori
Yoshida, Yasuto
Kaga, Hideyoshi
Katahira, Takehiro
Suzuki, Luka
Tamaki, Shoko
Sato, Junko
Goto, Hiromasa
Azuma, Kosuke
Shimizu, Tomoaki
Takahashi, Takuya
Yamashiro, Yuichiro
Watada, Hirotaka
Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
title Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
title_full Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
title_fullStr Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
title_full_unstemmed Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
title_short Effects of Synbiotic Supplementation on Chronic Inflammation and the Gut Microbiota in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study
title_sort effects of synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes mellitus: a randomized controlled study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7914668/
https://www.ncbi.nlm.nih.gov/pubmed/33567701
http://dx.doi.org/10.3390/nu13020558
work_keys_str_mv AT kanazawaakio effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT aidamasanori effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT yoshidayasuto effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT kagahideyoshi effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT katahiratakehiro effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT suzukiluka effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT tamakishoko effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT satojunko effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT gotohiromasa effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT azumakosuke effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT shimizutomoaki effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT takahashitakuya effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT yamashiroyuichiro effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy
AT watadahirotaka effectsofsynbioticsupplementationonchronicinflammationandthegutmicrobiotainobesepatientswithtype2diabetesmellitusarandomizedcontrolledstudy